T0	Participants 129 148	in healthy subjects
T1	Participants 537 579	to patients with hemophilia and inhibitors
T2	Participants 839 862	of N7-GP in healthy men
T3	Participants 864 996	METHODS A randomized, placebo-controlled, dose-escalation trial with five cohorts (N7-GP dose of 12.5-100 Î¼g kg(-1) ) was performed.
T4	Participants 997 1043	In each cohort, eight subjects were randomized
T5	Participants 1822 1864	in patients with hemophilia and inhibitors